Top news of the week: 06.01.2023.
Fate and J&J end deal that once promised $3B in milestones; biotech cuts staff
Fate Therapeutics said that it agreed with Johnson & Johnson to terminate a partnership they struck in 2020 to develop cancer immunotherapies, a deal that could have been worth as much as ...
Chris Viehbacher once again sets out to revamp R&D at a major biopharma. The last try led to his ouster
An outspoken Chris Viehbacher spent six years trying unsuccessfully to prod Sanofi’s multibillion-dollar R&D group into a more productive phase that relied less on partners like Regeneron ...
Scoop: MPM backs a new checkpoint inhibitor biotech in $80M raise
An MPM Capital-backed biotech based on the discovery of a new immune checkpoint inhibitor has secured about $80 million in financing, with former executives from Surface Oncology, Syndax ...
Executives Reunite at JPM as Biotech Kicks Off 2023
JP Morgan week is shaping up to approximate pre-pandemic attendance levels as executives return to San Francisco after two years of COVID-19-enforced absences.
The Pros and Cons of Working at a CRO
Clinical Research Organizations (CROs) can be a great option for pharma employees looking for a change of pace. To help with this decision, here are the pros and cons of working at a CRO.
'Sorry, Escape Bio closed': A neurodegenerative upstart exits bid to rival Biogen-Denali
A neurodegenerative disease-focused biotech that was attempting to go up against the billion-dollar pairing of Biogen and Denali has shuttered, Endpoints News has learned. Escape Bio had ...
On the road to human studies, next-gen gene editing contender Metagenomi hauls in an extra $100M
One of the up-and-comers in the gene editing field is banking an extra $100 million and boosting their B round to a hefty $275 million. The extra funding caps what was a busy year for ...
Allogene replaces Zai Lab-bound Rafael Amado with Zachary Roberts
CAR-T therapy company Allogene Therapeutics has swiftly named its replacement for executive vice president of research and development Rafael Amado, who has res